Production of 64Cu-labeled monobody for imaging of human EphA2-expressing tumors

Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer

“…Conjugation of the E1 monobody to reporter proteins (Rluc8 or EGFP) or chemicals (Cy5.5 or Cu 64 -NOTA) does not lead to loss of binding activity (35,44). Thus, it is likely that the monobody can be conjugated to therapeutic molecules such as proteins (toxins, enzymes and cytokines) and anticancer agents.…”

Protein scaffolds: antibody alternatives for cancer diagnosis and therapy

“…94 Another adnectin E1 against human EphA2, which is aberrantly expressed in diverse cancers, was used in an in vivo imaging study of the fluorescent probe E1-Rluc8 and a radiolabeled tracer 64 Cu-NOTA-E1 in a subcutaneous prostate tumor model, with results showing a strong signal, selective accumulation, and rapid clearance. 95,96 So far, two anti-PD-L1 adnectins, FN3hPD-L1-01 and BMS-986192, have been investigated for PD-L1 imaging, and the latter has shown good results in the clinic. 64 Cu-FN3hPD-L1 exhibited high specificity and a tumor-to-muscle ratio of 13 after 4 h in mice for PD-L1 expression quantification.…”